Evidence map›Paper›PMID 41058481›Full record

ArticlemAbs2025

Improving dual targeting selectivity in T-cell engagers via synapse-gated and affinity-tuned trispecific antibody design.

Peng Zhao, John Schardt, Chi-I Chiang, Pooja Shah, Gee Sung Eun, Jan Martinek, Matthew Cyr, Yoshimi Johnson, Bismark Amofah, Xiaoying Ye and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Peng ZhaoBiologics Engineering, R&D, Astrazeneca, Gaithersburg, MD, USA.
John SchardtBiologics Engineering, R&D, Astrazeneca, Gaithersburg, MD, USA.
Chi-I ChiangBiologics Engineering, R&D, Astrazeneca, Gaithersburg, MD, USA.
Pooja ShahBiologics Engineering, R&D, Astrazeneca, Gaithersburg, MD, USA.
Gee Sung EunOncology, R&D, Astrazeneca, Gaithersburg, MD, USA.
Jan MartinekDiscovery Sciences, Biopharmaceuticals R&D, Astrazeneca, Gaithersburg, MD, USA.
Matthew CyrBiologics Engineering, R&D, Astrazeneca, Gaithersburg, MD, USA.
Yoshimi JohnsonOncology, R&D, Astrazeneca, Gaithersburg, MD, USA.
Bismark AmofahBiologics Engineering, R&D, Astrazeneca, Gaithersburg, MD, USA.
Xiaoying YeProcess and Analytical Sciences, Biopharmaceuticals R&D, Astrazeneca, Gaithersburg, MD, USA.
Samuel EdwardsProcess and Analytical Sciences, Biopharmaceuticals R&D, Astrazeneca, Gaithersburg, MD, USA.
Xiaoru ChenClinical Pharmacology and Safety Sciences, R&D, Astrazeneca, Gaithersburg, MD, USA.
Mark PenneyOncology, R&D, Astrazeneca, Gaithersburg, MD, USA.
Wenhai LiuBiologics Engineering, R&D, Astrazeneca, Gaithersburg, MD, USA.
Chunning YangBiologics Engineering, R&D, Astrazeneca, Gaithersburg, MD, USA.ORCID 0009-0004-8173-0650
Keith RickertBiologics Engineering, R&D, Astrazeneca, Gaithersburg, MD, USA.
Amber LeeBiologics Engineering, R&D, Astrazeneca, Gaithersburg, MD, USA.ORCID 0000-0002-7793-1669
Sterling PayneBiologics Engineering, R&D, Astrazeneca, Gaithersburg, MD, USA.
Hanzhi ZhangBiologics Engineering, R&D, Astrazeneca, Gaithersburg, MD, USA.
Garrett KellyBiologics Engineering, R&D, Astrazeneca, Gaithersburg, MD, USA.
Chunlei WangProcess and Analytical Sciences, Biopharmaceuticals R&D, Astrazeneca, Gaithersburg, MD, USA.
Allison GerberOncology, R&D, Astrazeneca, Gaithersburg, MD, USA.
Kathy MulgrewOncology, R&D, Astrazeneca, Gaithersburg, MD, USA.
Rajat VarmaOncology, R&D, Astrazeneca, Gaithersburg, MD, USA.
Jonathan BoydDiscovery Sciences, Biopharmaceuticals R&D, Astrazeneca, Gaithersburg, MD, USA.
Xiuling LiBiologics Engineering, R&D, Astrazeneca, Gaithersburg, MD, USA.
John D BagertBiologics Engineering, R&D, Astrazeneca, Gaithersburg, MD, USA.ORCID 0000-0001-7768-2853
Even WalsengBiologics Engineering, R&D, Astrazeneca, Gaithersburg, MD, USA.
Yariv MazorBiologics Engineering, R&D, Astrazeneca, Gaithersburg, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T-cell engagers (TCEs) represent a powerful drug modality for redirecting a patient's own T cells to recognize and eradicate cancer cells. Although TCEs have been effective in treating hematological cancers, their broad application for solid tumors has been more challenging due to the absence of tumor-specific antigens. This often leads to on-target, off-tumor toxicities and a low therapeutic index (TI). Strategies for dual-antigen targeting of double-positive cancer cells over single-positive normal tissue may improve the TI of TCEs. In this study, we report the development and characterization of a conditional dual tumor-associated antigen (TAA)-targeting trispecific antibody (TriMab) TCE composed of a non-active anchoring arm (

Indexed as

Antibodies, BispecificImmunological SynapsesLung NeoplasmsT-LymphocytesAnimalsAntibody AffinityAntigens, NeoplasmCell Line, TumorFemaleHumansMiceXenograft Model Antitumor AssaysAntibodies, BispecificAntigens, NeoplasmDual-targetingtherapeutic indexTriMabtrispecific

Identifiers

PMID41058481
PMCPMC12520116

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.